Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease.
Journal
Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
01
10
2019
revised:
14
01
2020
accepted:
16
01
2020
pubmed:
22
1
2020
medline:
6
7
2021
entrez:
22
1
2020
Statut:
ppublish
Résumé
Proteolytic fragmentation of polyglutamine-expanded ataxin-3 is a concomitant and modifier of the molecular pathogenesis of Machado-Joseph disease (MJD), the most common autosomal dominant cerebellar ataxia. Calpains, a group of calcium-dependent cysteine proteases, are important mediators of ataxin-3 cleavage and implicated in multiple neurodegenerative conditions. Pharmacologic and genetic approaches lowering calpain activity showed beneficial effects on molecular and behavioural disease characteristics in MJD model organisms. However, specifically targeting one of the calpain isoforms by genetic means has not yet been evaluated as a potential therapeutic strategy. In our study, we tested whether calpains are overactivated in the MJD context and if reduction or ablation of calpain-1 expression ameliorates the disease-associated phenotype in MJD cells and mice. In all analysed MJD models, we detected an elevated calpain activity at baseline. Lowering or removal of calpain-1 in cells or mice counteracted calpain system overactivation and led to reduced cleavage of ataxin-3 without affecting its aggregation. Moreover, calpain-1 knockout in YAC84Q mice alleviated excessive fragmentation of important synaptic proteins. Despite worsening some motor characteristics, YAC84Q mice showed a rescue of body weight loss and extended survival upon calpain-1 knockout. Together, our findings emphasize the general potential of calpains as a therapeutic target in MJD and other neurodegenerative diseases.
Identifiants
pubmed: 31960910
pii: 5710189
doi: 10.1093/hmg/ddaa010
pmc: PMC7158375
doi:
Substances chimiques
Peptides
0
polyglutamine
26700-71-0
Ataxin-3
EC 3.4.19.12
Atxn3 protein, mouse
EC 3.4.19.12
Calpain
EC 3.4.22.-
Capn1 protein, mouse
EC 3.4.22.52
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
892-906Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL089517
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
Prog Neurobiol. 2016 Aug;143:1-35
pubmed: 27283248
Neurol Genet. 2018 Jan 18;4(1):e218
pubmed: 29379883
Cell Rep. 2016 Jun 28;16(1):79-91
pubmed: 27320912
Hum Mol Genet. 2014 Sep 15;23(18):4932-44
pubmed: 24817574
Cell Mol Life Sci. 2005 Sep;62(17):1913-24
pubmed: 15990959
J Biol Chem. 1999 May 14;274(20):14046-52
pubmed: 10318818
Acta Neuropathol Commun. 2016 Mar 31;4:34
pubmed: 27036949
Front Synaptic Neurosci. 2016 Mar 24;8:7
pubmed: 27047369
Trends Neurosci. 2010 Nov;33(11):513-23
pubmed: 20850189
Rare Dis. 2016 Apr 06;4(1):e1153778
pubmed: 27141414
J Neurochem. 2005 Aug;94(3):651-8
pubmed: 15992386
Hum Mol Genet. 2002 May 1;11(9):1075-94
pubmed: 11978767
Cell Death Dis. 2011 Nov 10;2:e228
pubmed: 22071633
Brain. 2015 Dec;138(Pt 12):3632-53
pubmed: 26490331
Nat Commun. 2012;3:1307
pubmed: 23250437
Lancet Neurol. 2016 Oct;15(11):1118
pubmed: 27647640
J Neurosci. 2017 Aug 9;37(32):7782-7794
pubmed: 28687604
J Neuropathol Exp Neurol. 1999 Jul;58(7):748-64
pubmed: 10411345
Neuropharmacology. 2018 May 1;133:94-106
pubmed: 29355642
Front Mol Neurosci. 2018 Oct 10;11:368
pubmed: 30364204
Hum Mol Genet. 2013 Feb 1;22(3):508-18
pubmed: 23100324
Brain. 2018 Feb 1;141(2):582-595
pubmed: 29324989
Neurobiol Dis. 2011 Feb;41(2):481-8
pubmed: 21047555
Curr Biol. 2005 May 24;15(10):918-28
pubmed: 15916948
Am J Hum Genet. 2016 May 5;98(5):1038-1046
pubmed: 27153400
Front Mol Neurosci. 2014 Jul 15;7:65
pubmed: 25076872
Sci Rep. 2016 Oct 12;6:35200
pubmed: 27731380
J Neurochem. 2016 Apr;137(2):253-65
pubmed: 26756888
Biomed Res Int. 2019 Feb 14;2019:4741252
pubmed: 30895192
J Biol Chem. 2019 Jan 11;294(2):644-661
pubmed: 30455355
Mol Neurodegener. 2018 Jun 22;13(1):31
pubmed: 29929540
Nature. 2000 May 18;405(6784):360-4
pubmed: 10830966
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Curr Pharm Des. 2017;23(5):753-775
pubmed: 28025946
Nat Rev Drug Discov. 2016 Dec;15(12):854-876
pubmed: 27833121
Brain. 2017 May 1;140(5):1280-1299
pubmed: 28334907
Cell Death Differ. 2015 Mar;22(3):433-44
pubmed: 25257175
Nat Chem Biol. 2008 May;4(5):295-305
pubmed: 18391949
J Biol Chem. 2007 Jun 29;282(26):18851-6
pubmed: 17488727
Prog Neurobiol. 2010 Aug;91(4):313-48
pubmed: 20438797
J Neurosci. 2008 Nov 26;28(48):12713-24
pubmed: 19036964
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2628-32
pubmed: 8464868
Brain. 2012 Aug;135(Pt 8):2428-39
pubmed: 22843411
Biochem J. 2012 Nov 1;447(3):335-51
pubmed: 23035980
Trends Neurosci. 2016 Apr;39(4):235-245
pubmed: 26874794
Neuroscientist. 2017 Jun;23(3):221-231
pubmed: 27188456
Neurobiol Dis. 2014 Feb;62:533-42
pubmed: 24269729
Sci Signal. 2008 Apr 08;1(14):re1
pubmed: 18398107
Biomed Res Int. 2014;2014:701758
pubmed: 25309920
Mol Cell Biol. 2001 Mar;21(6):2213-20
pubmed: 11238954
Brain. 2011 Jul;134(Pt 7):1925-42
pubmed: 21653538
Neurosci Lett. 2000 Jun 2;286(2):149-53
pubmed: 10825658
PLoS One. 2013 May 31;8(5):e64627
pubmed: 23741357
Med Res Rev. 2019 Mar;39(2):608-630
pubmed: 30260518
J Clin Neurol. 2019 Apr;15(2):271-272
pubmed: 30938113
Mol Ther. 2013 Oct;21(10):1898-908
pubmed: 23765441
J Biol Chem. 2012 Apr 13;287(16):13182-93
pubmed: 22367208
Nature. 2011 Nov 23;480(7378):543-6
pubmed: 22113611
J Neurosci. 2002 Jun 15;22(12):4842-9
pubmed: 12077181
PLoS One. 2013 Apr 23;8(4):e62043
pubmed: 23626768
Neurobiol Dis. 2008 Jul;31(1):89-101
pubmed: 18502140